drugset / Trial / NCT04984876
Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy
RandomizedParallel-groupTriple-blindTreatment
Summary
This was a 52-week, Phase 3 multi-center, randomized, double-blind and placebo-controlled study to assess the safety and clinical efficacy of two dosing regimens of ligelizumab (240 mg and 120 mg) SC q4w (subcutaneous injection every 4 weeks) in participants with a medically confirmed diagnosis of Immunoglobulin E (IgE) mediated peanut allergy.
Timeline
- Start
- 2021-12-07
- Primary completion
- 2023-11-27
- Completion
- 2023-11-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ligelizumab | Monoclonal antibody | 120 mg | Subcutaneous |
| Subject | Ligelizumab | Monoclonal antibody | 240 mg | Subcutaneous |